-
15 September 2024
-
15 September 2024
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
PARIS, FRANCE, 15 September 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today detailed final overall survival (OS) data from the Phase III CONTACT-02 trial investigating the combination of Cabometyx® (cabozantinib) and atezolizumab in metastatic ca...
-
22 January 2024
-
22 January 2024
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
PARIS, FRANCE, 22 January 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today new data to be presented for Cabometyx® (cabozantinib) in combination with immunotherapy across indications at the upcoming American Society of Clinical Oncology Genitourin...
-
23 August 2023
-
23 August 2023
Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX®) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer
PARIS, FRANCE, 02 July 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trial...
-
21 August 2023
-
21 August 2023
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prosta...
-
15 August 2023
-
15 August 2023
Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer
PARIS, FRANCE, 25 March 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) have recommended approval of Cabometyx as a monotherapy for the treatm...
-
23 August 2023
-
23 August 2023
Ipsen donates €2 million to the Institut Pasteur to support research on COVID-19
Paris – 04/01/2020 – The biopharmaceutical group Ipsen has answered call of the Institut Pasteur and announces today a donation of €2 million dedicated to COVID-19 research. Since January, the Institut Pasteur has devoted a portion of its research ...
-
23 August 2023
-
23 August 2023
Ipsen announces publication of first matching-adjusted indirect comparison of Cabometyx® (cabozantinib) versus regorafenib in advanced hepatocellular carcinoma in Advances in Therapy
PARIS, FRANCE, 19 May 2020 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that data from the matching-adjusted indirect comparison (MAIC) of Cabometyx® (cabozantinib) versus Stivarga® (regorafenib) for the second-line (2L) treatment of patient...
-
23 August 2023
-
23 August 2023
-
24 August 2023
-
24 August 2023
-
23 August 2023
-
23 August 2023
Ipsen annonce la publication dans Advances in Therapy de la première comparaison indirecte ajustée par appariement entre Cabometyx® (cabozantinib) et le régorafénib dans le traitement du carcinome hépatocellulaire avancé
PARIS, FRANCE, le 19 mai 2020 –Ipsen (Euronext : IPN ; ADR : IPSEY) annonce que les résultats de la comparaison indirecte ajustée par appariement (MAIC) entre Cabometyx® (cabozantinib) et Stivarga® (régorafénib) pour le traitement de deuxièm...